دورية أكاديمية
Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.
| العنوان: | Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer. |
|---|---|
| المؤلفون: | Sutherland L; Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA., Lang J; Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA., Gonzalez-Juarbe N; J. Craig Venter Institute, Rockville, MD 20850, USA.; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA., Pickett BE; Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA. |
| المصدر: | Current issues in molecular biology [Curr Issues Mol Biol] 2024 Jul 06; Vol. 46 (7), pp. 7114-7133. Date of Electronic Publication: 2024 Jul 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 100931761 Publication Model: Electronic Cited Medium: Internet ISSN: 1467-3045 (Electronic) Linking ISSN: 14673037 NLM ISO Abbreviation: Curr Issues Mol Biol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : Basel, Switzerland : MDPI Original Publication: Wymondham, Norfolk, UK : Caister Academic Press, |
| مستخلص: | Estrogen receptor-positive (ER+) breast cancer is common among postmenopausal women and is frequently treated with Letrozole, which inhibits aromatase from synthesizing estrogen from androgens. Decreased estrogen slows the growth of tumors and can be an effective treatment. The increase in Letrozole resistance poses a unique problem for patients. To better understand the underlying molecular mechanism(s) of Letrozole resistance, we reanalyzed transcriptomic data by comparing individuals who responded to Letrozole therapy (responders) to those who were resistant to treatment (non-responders). We identified SOX11 and S100A9 as two significant differentially expressed genes (DEGs) between these patient cohorts, with "PLK1 signaling events" being the most significant signaling pathway. We also identified PRDX4 and E2F8 gene products as being the top mechanistic transcriptional markers for ER+ treatment resistance. Many of the significant DEGs that we identified play a known role in ER+ breast cancer or other types of cancer, which partially validate our results. Several of the gene products we identified are novel in the context of ER+ breast cancer. Many of the genes that we identified warrant further research to elucidate the more specific molecular mechanisms of Letrozole resistance in this patient population and could potentially be used as prognostic markers with further wet lab validation. We anticipate that these findings could contribute to improved detection and therapeutic outcomes in aromatase-resistant ER+ breast cancer patients. |
| References: | Breast Cancer Res. 2021 Aug 15;23(1):85. (PMID: 34392831) Cancer Manag Res. 2019 Nov 14;11:9685-9699. (PMID: 31814764) Breast Cancer Res. 2011 Mar 01;13(2):R21. (PMID: 21362200) Front Oncol. 2022 Jun 02;12:903016. (PMID: 35719948) Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. (PMID: 26122181) Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. (PMID: 29581135) PLoS Comput Biol. 2022 Mar 11;18(3):e1009926. (PMID: 35275931) Biochim Biophys Acta Rev Cancer. 2023 May;1878(3):188891. (PMID: 37001615) Nucleic Acids Res. 2012 Jan;40(Database issue):D54-6. (PMID: 22009675) Bioinformatics. 2009 Jan 1;25(1):75-82. (PMID: 18990722) Oncotarget. 2016 Apr 26;7(17):23757-71. (PMID: 26992224) Cancer Biol Ther. 2018 Apr 3;19(4):335-345. (PMID: 29333926) J Cell Biochem. 2022 Mar;123(3):581-600. (PMID: 35014077) Cancer Cell Int. 2022 Mar 5;22(1):108. (PMID: 35248028) PLoS One. 2023 Jun 28;18(6):e0287602. (PMID: 37379307) BMC Syst Biol. 2014;8 Suppl 4:S11. (PMID: 25521941) Life Sci. 2022 Dec 1;310:121074. (PMID: 36243120) Bioinformatics. 2018 Oct 15;34(20):3600. (PMID: 29788404) Cancer Diagn Progn. 2022 Nov 3;2(6):720-730. (PMID: 36340459) Cell Rep. 2013 Jun 27;3(6):2021-32. (PMID: 23770244) Cancer Res. 2015 Jan 15;75(2):405-14. (PMID: 25480943) Int J Biol Sci. 2014 May 14;10(5):566-75. (PMID: 24910535) PLoS One. 2011 Feb 11;6(2):e16833. (PMID: 21347291) Matrix Biol. 2015 Apr;43:42-60. (PMID: 25728938) Breast Cancer Res Treat. 2007;105 Suppl 1:7-17. (PMID: 17912633) N Engl J Med. 2007 May 3;356(18):1809-22. (PMID: 17476007) Cancer. 2003 Aug 1;98(3):474-83. (PMID: 12879463) BMC Cancer. 2009 Jun 16;9:188. (PMID: 19531263) Cancer. 2019 Nov 1;125(21):3714-3728. (PMID: 31318440) Int J Mol Sci. 2022 Jan 20;23(3):. (PMID: 35163043) J Intern Med. 2013 Feb;273(2):114-27. (PMID: 23216836) Sci Rep. 2017 Mar 13;7:44244. (PMID: 28287129) NPJ Breast Cancer. 2022 May 6;8(1):60. (PMID: 35523804) J Exp Clin Cancer Res. 2020 Sep 30;39(1):204. (PMID: 32993787) Technol Cancer Res Treat. 2019 Jan 1;18:1533033819864313. (PMID: 31311441) Radiother Oncol. 2022 Jun;171:91-100. (PMID: 35429503) Curr Protoc Bioinformatics. 2014 Sep 08;47:8.13.1-24. (PMID: 25199793) iScience. 2023 Jul 26;26(9):107466. (PMID: 37636034) Oxid Med Cell Longev. 2019 Aug 8;2019:5357649. (PMID: 31485295) PeerJ. 2022 Mar 21;10:e13090. (PMID: 35341048) Pharmacol Ther. 2016 Jul;163:1-23. (PMID: 27130805) Bone. 2020 Aug;137:115390. (PMID: 32353565) Front Genet. 2021 Feb 01;12:620705. (PMID: 33597971) Cancer Manag Res. 2020 Nov 04;12:11243-11255. (PMID: 33177875) Clin Cancer Res. 2020 Aug 1;26(15):4120-4134. (PMID: 32245900) Cell Commun Signal. 2019 Nov 21;17(1):154. (PMID: 31752925) Breast Cancer Res. 2013 Mar 18;15(2):R25. (PMID: 23506684) Front Oncol. 2020 Jan 24;9:1473. (PMID: 32038996) BMC Cancer. 2021 Feb 10;21(1):149. (PMID: 33568081) Front Cell Infect Microbiol. 2022 Sep 20;12:1009328. (PMID: 36204651) J Exp Clin Cancer Res. 2021 Jan 7;40(1):19. (PMID: 33413549) Cells. 2020 Jul 08;9(7):. (PMID: 32650578) Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. (PMID: 36370105) Viruses. 2018 Nov 18;10(11):. (PMID: 30453684) Breast Cancer Res. 2019 Jan 7;21(1):2. (PMID: 30616553) Oncol Lett. 2018 Jun;15(6):9216-9230. (PMID: 29844824) CA Cancer J Clin. 2022 Nov;72(6):524-541. (PMID: 36190501) Biochim Biophys Acta Rev Cancer. 2022 Mar;1877(2):188692. (PMID: 35122882) Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. (PMID: 17912634) Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308) Clin Exp Metastasis. 2007;24(5):341-51. (PMID: 17505812) J Bioinform Syst Biol. 2022;5(4):119-135. (PMID: 36873459) Am J Transl Res. 2020 Sep 15;12(9):5844-5865. (PMID: 33042464) Breast Cancer (Auckl). 2016 Mar 13;10:13-23. (PMID: 26997868) Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: 33921767) Nucleic Acids Res. 2021 Jan 8;49(D1):D1302-D1310. (PMID: 33196847) J Biol Chem. 2012 Jul 13;287(29):24631-40. (PMID: 22645147) EMBO J. 2012 Oct 3;31(19):3871-84. (PMID: 22903062) Carcinogenesis. 2015 Jan;36(1):122-32. (PMID: 25421723) Diagnostics (Basel). 2021 Mar 09;11(3):. (PMID: 33803206) Am J Physiol Cell Physiol. 2022 Jul 1;323(1):C29-C45. (PMID: 35584326) FEBS J. 2011 Jan;278(1):16-27. (PMID: 21087457) Int J Cancer. 2006 Sep 15;119(6):1403-11. (PMID: 16615109) Oncotarget. 2017 Oct 27;8(60):102739-102758. (PMID: 29254284) Eur J Cell Biol. 2015 Dec;94(12):547-63. (PMID: 26340821) Mol Cancer Ther. 2016 Jul;15(7):1427-35. (PMID: 27330107) BMC Cancer. 2008 May 02;8:129. (PMID: 18454859) EClinicalMedicine. 2022 Nov 24;55:101753. (PMID: 36444211) Semin Diagn Pathol. 2015 Sep;32(5):362-9. (PMID: 25770732) Oncotarget. 2016 Mar 15;7(11):13106-21. (PMID: 26894864) J Natl Cancer Inst. 2015 Jun 10;107(9):. (PMID: 26063794) PeerJ. 2023 Sep 29;11:e16088. (PMID: 37790614) Microb Pathog. 2022 Dec;173(Pt A):105816. (PMID: 36209971) Transl Oncol. 2017 Feb;10(1):22-32. (PMID: 27888710) Oncogene. 2014 Sep 25;33(39):4767-77. (PMID: 24141779) Life Sci Alliance. 2019 Nov 14;2(6):. (PMID: 31727800) J Clin Oncol. 2014 Apr 1;32(10):1050-7. (PMID: 24590635) Clin Biochem. 2021 Jun;92:9-18. (PMID: 33713636) Biochem Pharmacol. 2006 Nov 30;72(11):1622-31. (PMID: 16846592) J Biol Chem. 2010 Jun 4;285(23):17734-43. (PMID: 20385561) Cell Commun Signal. 2020 Jan 27;18(1):13. (PMID: 31987043) Commun Biol. 2021 May 17;4(1):590. (PMID: 34002013) Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166745. (PMID: 37164180) G3 (Bethesda). 2019 Jul 9;9(7):2089-2096. (PMID: 31088905) Cell Oncol (Dordr). 2022 Apr;45(2):227-239. (PMID: 35303290) Nat Commun. 2018 Nov 9;9(1):4718. (PMID: 30413718) Curr Cancer Drug Targets. 2008 Jun;8(4):243-52. (PMID: 18537548) Front Pharmacol. 2022 Aug 25;13:961941. (PMID: 36091799) J Biol Chem. 2021 Jan-Jun;296:100665. (PMID: 33895140) Pathol Oncol Res. 2011 Sep;17(3):753-8. (PMID: 21479875) Comput Struct Biotechnol J. 2023;21:1403-1413. (PMID: 36785619) Development. 2010 Mar;137(5):775-84. (PMID: 20147379) Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959) Breast Cancer Res Treat. 2020 Jul;182(2):267-282. (PMID: 32445177) JAMA Surg. 2014 Feb;149(2):125-9. (PMID: 24306257) Clin Cancer Res. 2005 Sep 15;11(18):6442-9. (PMID: 16166418) Cancer Lett. 2015 Jun 1;361(2):262-70. (PMID: 25779674) Mediators Inflamm. 2020 May 5;2020:8635158. (PMID: 32454796) Gene. 2023 Apr 5;859:147201. (PMID: 36646187) Nat Commun. 2022 Mar 18;13(1):1481. (PMID: 35304461) J Biol Chem. 1997 Apr 4;272(14):9496-502. (PMID: 9083090) Int J Mol Sci. 2022 May 17;23(10):. (PMID: 35628390) F1000Res. 2021 Apr 29;10:330. (PMID: 34868553) Cancer Cell Int. 2014 Apr 17;14:34. (PMID: 24739220) Biochim Biophys Acta. 2012 Dec;1820(12):1926-39. (PMID: 22884656) Clin Exp Metastasis. 2005;22(3):237-46. (PMID: 16158251) Nat Commun. 2020 Oct 30;11(1):5488. (PMID: 33127913) Clin Med Res. 2009 Jun;7(1-2):4-13. (PMID: 19574486) Exp Ther Med. 2021 Sep;22(3):1030. (PMID: 34373716) Endocr Relat Cancer. 2019 Jun;26(6):615-628. (PMID: 30978702) Biomark Res. 2019 Aug 06;7:16. (PMID: 31402980) Nucleic Acids Res. 2012 Sep 1;40(17):e133. (PMID: 22638577) |
| فهرسة مساهمة: | Keywords: breast cancer; estrogen receptor; letrozole; transcriptional mechanisms; treatment resistance |
| تواريخ الأحداث: | Date Created: 20240726 Latest Revision: 20240728 |
| رمز التحديث: | 20240728 |
| مُعرف محوري في PubMed: | PMC11275280 |
| DOI: | 10.3390/cimb46070424 |
| PMID: | 39057065 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1467-3045 |
|---|---|
| DOI: | 10.3390/cimb46070424 |